Japanese Sanofi To Quit Marketing Agreements For Nine Drugs (Japan)
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis KK, the French drug maker's Japanese unit, has decided to end its marketing partnerships and handle its own sales of flagship drugs in Japan. The firm's president said the change in strategy is part of its effort to double the 2005 Japanese sales level next year. The marketing partnerships include Chugai Pharmaceutical, handling seven drugs, which is to be canceled at the end of this year. Other partnerships are with Amoban for a sleep-disorder treatment, and Menamin for an anti-inflammatory painkiller, and they are to be ended in January. (Click here for more - may require subscription
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.